A Prospective Cohort Study on the Epidemiological Investigation, Diagnosis, and Treatment of Hepatic Encephalopathy
A legfontosabb adatok
- Ki végzi
- The First Affiliated Hospital with Nanjing Medical University
- Hol
- Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toborzás még nem indult
- Résztvevők
- 700 fő, tervezett
- Kezdés
- 2026. okt. 1.
- Várható befejezés
- 2028. márc. 31.
- A vizsgálat típusa
- Megfigyeléses, 6 csoport
- A vizsgált kezelések
- wechat mini-program
- A regiszteradat frissítve
- 2026. október 1.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with liver cirrhosis (scarring of the liver), and also healthy volunteers. It studies hepatic encephalopathy, a brain problem caused by liver disease.
- Életkor
- 18 to 75 years
- Nem
- All sexes
- A betegség stádiuma
- Liver cirrhosis diagnosed by doctors from imaging, elastography (a liver stiffness scan), biopsy or symptoms. Healthy volunteers can also join.
- Korábbi kezelés
- People who took part in another clinical trial in the past 3 months cannot join.
A részvétel fő kizáró okai
- Women who are pregnant, planning pregnancy or breastfeeding
- Not able to use a smartphone with WeChat mini-programs, or no stable internet
- Red-green color blindness or other vision problems that cannot be corrected
- Heart, lung or kidney failure, or unstable vital signs
- Other clinical trial in the past 3 months
A regiszter feltételei, szó szerint
Mind a 12 feltétel megnézéseKevesebb
Ki vehet részt
- For patients with liver cirrhosis and the general healthy population, the diagnosis of liver cirrhosis is made by doctors based on imaging, elastography, biopsy or clinical symptoms
- The patients themselves and their accompanying family members have smart phones, are proficient in using WeChat and mini-programs, and have a stable network environment
- They voluntarily sign the informed consent form, have good compliance, and fully understand this study
Ki nem vehet részt
- Heart, lung, or kidney failure or unstable vital signs
- Age < 18 years old
- Women planning to get pregnant, already pregnant or during lactation
- Incomplete relevant data information required
- Unable to proficiently use WeChat mini-program or unstable network environment
- Red-green color blindness or other irreparable visual impairments
- Unwilling to participate in the study or unable to sign the informed consent form
- Any other situation that may interfere with the study assessment, increase the risk for the subjects, or affect their completion of the study, as judged by the researcher and deemed unsuitable for participating in this study
- Have participated in or are currently participating in other clinical trials within the past 3 months
Nézd meg, megfelelhetsz-e
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 75 év között vagy?
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Purpose Hepatic encephalopathy (HE) is a serious complication of liver cirrhosis that can cause memory loss, slow reaction, and even coma. In China, large-scale epidemiological data on HE are lacking, early diagnosis remains difficult, and treatment needs improvement. This study aims to investigate the prevalence of HE in Chinese liver disease patients and to explore better diagnostic methods and treatment strategies.
A teljes eredeti leírásKevesebb
Design This is a prospective, multicenter cohort study led by Jiangsu Province Hospital, in collaboration with 7 other hospitals in Jiangsu Province. Between April 2026 and December 2029, the study plans to enroll over 700 patients with liver cirrhosis and 120 healthy volunteers.
What participants will do Participants will use a WeChat mini-program to perform simple cognitive tests (e.g., reaction speed, attention) regularly. They will be followed up at month 1, 3, 6 after enrollment, and then every six months. The research team will collect routine laboratory results, medication records, and quality-of-life data.
Benefits and risks Participants will receive closer health monitoring, which may help detect changes early. The study involves no additional drugs or invasive procedures, so risks are very low. All personal information will be kept strictly confidential and used only for medical research.
Voluntary participation Participation is completely voluntary, and participants can withdraw at any time without affecting their routine medical care.
A vizsgálat 6 csoportja
- non-CHE
Patients who did not develop covert hepatic encephalopathy during the follow-up period
Kezelés: wechat mini-program
- CHE
Patients who develop covert hepatic encephalopathy during the follow-up period
Kezelés: wechat mini-program
- liver cirrhosis with sarcopenia
Patients who develop sarcopenia during the follow-up period
- liver cirrhosis without sarcopenia
Patients who did not develop sarcopenia during the follow-up period
- liver cirrhosis with decline in quality of life
During the follow-up period, there was a decline in quality of life.
- liver cirrhosis without decline in quality of life
During the follow-up period, there was not a decline in quality of life.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Illeszkedési kérdések
- Forrás: NCT07612670: ki vehet részt
- A regiszteradat frissítve
- 2026. október 1.